About: Guidance for the Procurement of COVID‐19 Convalescent Plasma: Differences between High and Low‐Middle Income Countries

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Guidance for the Procurement of COVID‐19 Convalescent Plasma: Differences between High and Low‐Middle Income Countries Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Guidance for the Procurement of COVID‐19 Convalescent Plasma: Differences between High and Low‐Middle Income Countries
Creator	Burnouf, Thierry Bloch, Evan Goel, Ruchika Al-Riyami, Arwa Ang, Ai Blood, Canadian Cross, Deangelis, Vincenzo Dumont, Larry Kong, Red Wendel, Silvano
Source	Medline; PMC
abstract	BACKGROUND AND OBJECTIVES: COVID‐19 convalescent plasma (CCP) has been used, predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low and middle‐income countries (LMICs) for which data are lacking. MATERIALS AND METHODS: A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and hematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self‐identified expertise and interest. Here, the donor and product‐related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices. RESULTS: The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre‐donation qualification and operational considerations could impede wide adoption. CONCLUSION: There has been wide scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.
has issue date	2020-06-13(xsd:dateTime)
bibo:doi	10.1111/vox.12970
bibo:pmid	32533868
has license	no-cc
sha1sum (hex)	94ed5f525fb14e41620682955a4ab7672b3f220b
schema:url	https://doi.org/10.1111/vox.12970
resource representing a document's title	Guidance for the Procurement of COVID‐19 Convalescent Plasma: Differences between High and Low‐Middle Income Countries
has PubMed Central identifier	PMC7323328
has PubMed identifier	32533868
schema:publication	Vox Sang
resource representing a document's body	covid:94ed5f525fb14e41620682955a4ab7672b3f220b#body_text
is schema:about of	named entity 'Osman' named entity 'Cynthia' named entity 'South African National Blood Service' named entity 'HBV' named entity 'apheresis' named entity 'platelet' named entity 'PPE' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'nucleocapsid protein' named entity 'antibodies' named entity 'ISBT' named entity 'antibody testing' named entity 'hyperimmune globulin' named entity 'homemade masks' named entity 'pathogens' named entity 'convalescent plasma' named entity 'Europe' named entity 'plasma' named entity 'comorbid' named entity 'apheresis' named entity 'plasma' named entity 'antibody testing' named entity 'blood product' named entity 'SARS' named entity 'COVID-19 disease' named entity 'HLA' named entity 'SARS-CoV-2' named entity 'plasma' named entity 'apheresis' named entity 'hemoglobin' named entity 'red blood cells' named entity 'Neutralizing antibodies' named entity 'titer' named entity 'HLA' named entity 'LMIC' named entity 'COVID' named entity 'transfusion related acute lung injury' named entity 'plasma' named entity 'HEV' named entity 'Pathogen' named entity 'hepatitis' named entity 'COVID' named entity 'blood donation' named entity 'immunoglobulins' named entity 'men who have sex with men' named entity 'immune response' named entity 'blood products' named entity 'Plasma collection' named entity 'antibody' named entity 'antibody testing' named entity 'COVID' named entity 'COVID-19' named entity 'transfusion' named entity 'South Africa' named entity 'hepatitis E virus' named entity 'quality assurance' named entity 'public health surveillance' named entity 'viruses' named entity 'plasma' named entity 'plasma' named entity 'SARS' named entity 'COVID' named entity 'North America' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'laboratory testing' named entity 'infectivity' named entity 'epidemics'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software